The introduction of a cotesting strategy in the opportunistic setting could represent the best option in the transition time from cytology to HPV DNA–based screening.
1Department of Gynecological Oncology, Regina Elena Institute, Roma; 2Department of Gynecological Oncology, European Institute of Oncology, Milano; 3Department of Obstetrics and Gynecology, S. Orsola-Malpighi University Hospital, Bologna; 4Department of Gynecological Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova; 5Department of Obstetrics and Gynecology, Vita Salute San Raffaele University School of Medicine, Milano and 6Department of Gynecology and Obstetrics, University of Torino, Torino, Italy
Reprint requests to: Mario Preti, MD, Corso Orbassano 227, 10137 Torino, Italy. E-mail: email@example.com
The authors have declared they have no conflicts of interest.